Roche chemo-immunotherapy combo meet NSCLC... A Phase III study (IMpower150) sponsored by Roche has shown that a combo of the companys PD-L1 blocker atezolizumab (Tecentriq) and VEGF blocking antibody bevacizumab (Avastin) plus paclitaxel + carboplatin … more ➔
Orphazyme raises €80m in oversubscribed...Danish heat shock protein specialist Orphazyme raised €80m+ through an IPO at Nasdaq Copenhagen adding momentum to the current upswing of European biotech. more ➔
Antibiotic Resistance: EU SME alliance cal...The BEAM Alliance has called out worldwide stakeholders to support SME-driven innovation to revive the product pipeline fighting antimicrobial resistance (AMR). In a position paper the alliance … more ➔
Bayer inks US$1.55bn cancer deal with Loxo...German Bayer AG has acquired ex-US commercialisation rights to Loxo Oncology Incs Phase II lead larotrectinib (LOXO-101), which targets TRK (tropomyosin receptor kinase) fusions in 17 cancer types, … more ➔
Bill Gates invests into Alzheimer’s... Billionaire Bill Gates announced he is going to invest US$50m private money into the Dementia Discovery Fund (DDF) to support fresh ideas for developing Alzheimer drugs and diagnostics. The venture … more ➔
CHMP recommends EU marketing approval of...The European Medicines Agencys Committee for Medicinal Products for Human Use (CHMP) recommended seven medicines for approval, including two orphan medicines, plus three generics at its November 2017 … more ➔
BIO-Europe more popular than ever More than 4,000 participants from all over the globe visited Berlin in early November to take part in this years BIO-Europe. The event continues to be on the upswing – like the biotech industry itself. more ➔
Spain pushes circular bioeconomyConversion of agricultural waste into useful products is a worldwide need. As part of the European Project Valor Plus, Spanish biotechindustry association ASEBIO invited its members to visit the recently … more ➔
Stem cells cure deadly human skin diseaseFor the first time researchers at universities Bochum (Germany), Salzburg (Austria), and Modena (Italy) have shown that autologous transgenic keratinocyte cultures can regenerate an entire, fully functional … more ➔
InflaRx Announces Pricing of Initial Publi... German inflammation and autoimmunity specialist InflaRx AG (Jena) announced it will offer 6,667,000 common shares at an Nasdaq initial public offering price of $15.00 per common share, resulting in … more ➔